Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
Open Access
- 6 August 2025
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-10
Abstract
Chronic systemic inflammation is a key driver of polycythemia vera (PV) progression, but the immunomodulatory effects of current treatments remain poorly defined. The neutrophil-to-lymphocyte ratio (NLR) is an accessible biomarker of systemic inflammation proven in other contexts, but its role in monitoring PV disease activity has not been established. Using data from three of the largest PV clinical trials, we evaluated the effects of PV therapies on NLR and its relationship with molecular response and clinical outcomes. In 404 hematocrit-controlled patients from the ECLAP study, hydroxyurea (HU) failed to significantly lower NLR (p = 0.11) due to the parallel declines in ANC and ALC. Neither leukocyte counts nor NLR were significantly reduced by phlebotomy in ECLAP patients treated without cytoreductive therapy. In contrast, the Low-PV study showed that while phlebotomy tended to increase NLR, low-dose ropeginterferon alfa-2b (Ropeg) significantly reduced NLR (−18.2% and −36.3% in patients with low and high baseline NLR, respectively) by suppressing ANC rather than lymphocytes. NLR reduction correlated with the primary Low-PV endpoint (p = 0.021) and reduction of JAK2 variant allele frequency (VAF) [1]. The PROUD-PV/CONTINUATION-PV study confirmed the superior effect of Ropeg over HU, with a significantly greater NLR reduction at 60 months (−56.5% versus −33.6%, respectively, p = 0.019) in patients with high baseline NLR. Moreover, NLR reduction was associated with decreased JAK2V617F VAF (p < 0.0001) and improved event-free survival (p = 0.010). These findings identify NLR as a dynamic biomarker of treatment response and prognosis in PV and support its incorporation into routine monitoring.Keywords
This publication has 31 references indexed in Scilit:
- The triple A model (age, absolute neutrophil count, absolute lymphocyte count‐AAA) predicts survival and thrombosis in polycythemia veraAmerican Journal of Hematology, 2024
- A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte countAmerican Journal of Hematology, 2023
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsThe Lancet Haematology, 2022
- Systemic inflammation markers and cancer incidence in the UK BiobankEuropean Journal of Epidemiology, 2021
- Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialThe Lancet Haematology, 2021
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyThe Lancet Haematology, 2020
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothLeukemia, 2016
- Distribution of lymphocyte subpopulations in patients with polycythemia veraHuman Immunology, 2015
- Progress and challenges in translating the biology of atherosclerosisNature, 2011